Detalhe da pesquisa
1.
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression.
Nat Immunol
; 22(6): 735-745, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34017124
2.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Lancet Oncol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38710187
3.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 436, 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38589856
4.
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Lancet Oncol
; 24(7): 744-756, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37329891
5.
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Lancet Oncol
; 24(5): 496-508, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142372
6.
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.
Oncologist
; 28(12): e1209-e1218, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597246
7.
Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features.
Mod Pathol
; 36(2): 100012, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36853785
8.
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
Nature
; 552(7683): 116-120, 2017 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29186113
9.
Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report.
World J Surg Oncol
; 21(1): 118, 2023 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36998040
10.
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer.
Br J Cancer
; 127(3): 394-407, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35264786
11.
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 22(6): 779-789, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33961795
12.
Personalized therapeutic strategies in HER2-driven gastric cancer.
Gastric Cancer
; 24(4): 897-912, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33755862
13.
The genomic landscape of response to EGFR blockade in colorectal cancer.
Nature
; 526(7572): 263-7, 2015 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26416732
14.
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 271-282, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838007
15.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 261-270, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838015
16.
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy.
Int J Cancer
; 147(11): 3215-3223, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32875550
17.
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Invest New Drugs
; 38(6): 1774-1783, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32410080
18.
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions.
Int J Mol Sci
; 21(17)2020 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32883002
19.
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
Oncologist
; 24(10): 1395-1402, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30952821
20.
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 563, 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38711003